BNC105 / Bionomics  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BNC105 / Bionomics
ACTRN12607000520437: A Phase 1, Two-Stage, Dose-Escalation Study of BNC105P, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors

Completed
1
30
 
Bionomics Limited, Bionomics Limited
Solid tumours
 
 
NCT03454165: A Study of BNC105P Combined With Ibrutinib

Completed
1
6
US
BNC105P, Ibrutinib
Dartmouth-Hitchcock Medical Center
Chronic Lymphocytic Leukemia
01/21
01/21

Download Options